Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

By sjmartinez • February 12, 2025

Schiantarelli J, Benamar M, Park J, Sax HE, Oliveira G, Bosma-Moody A, Campbell KM, Liu D, Johnson DB, Rodig S, Wu CJ, Hodi FS, Ribas A, Van Allen E, Haq R. Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer Cell. 2025 Feb 10;43(2):308-316.e6. doi: 10.1016/j.ccell.2025.01.009. PMID: 39933900.

Tags: acquired resistance, Hematology/Oncology, immune checkpoint inhibitors, metastatic melanoma, Publications, SEC24, STING signaling

Related Posts

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi[...]

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias

Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar[...]

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson[...]